ABEO Stock Risk & Deep Value Analysis
Abeona Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ABEO Stock
We analyzed Abeona Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABEO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ABEO Risk Analysis & Red Flags
What Could Go Wrong
The company is burning cash with quarterly losses increasing to $20.5 million (Q4 2025). While cash stands at $191.4 million, if ZEVASKYN's commercial ramp continues to be significantly slower than expected, the company will need further capital raises, potentially leading to substantial shareholder dilution and downward pressure on the stock.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Low
Competitive
Low
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Q4 2025 revenue miss and slow commercial ramp ($2.4M product revenue) for ZEVASKYN.
- ⚠
Mounting quarterly operating losses ($20.5M in Q4 2025) indicating significant cash burn.
- ⚠
Substantial share dilution noted over the past year.
- ⚠
Unnamed insider proposes stock sale on March 31, 2026, and prior sale on Jan 22, 2026.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or slower than expected ZEVASKYN revenue growth
- 📅
Further manufacturing disruptions impacting ZEVASKYN supply
- 📅
Unexpected safety concerns or adverse events with ZEVASKYN
When to Reconsider
- 🚪
Quarterly product revenue from ZEVASKYN fails to show significant sequential acceleration for two consecutive quarters.
- 🚪
Cash position drops below $100 million without a clear path to profitability or new funding secured.
- 🚪
Adverse clinical or safety events with ZEVASKYN are reported by regulatory bodies.
Unlock ABEO Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Abeona Therapeutics Inc (ABEO) Do?
Market Cap
$292.09M
Sector
Healthcare
Industry
Biotechnology
Employees
136
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Visit Abeona Therapeutics Inc WebsiteInvestment Thesis
Abeona Therapeutics offers significant 10x growth potential by leveraging its approved, first-in-class gene therapy, ZEVASKYN, for the ultra-rare and high-need RDEB market. With a strong cash position and active commercialization efforts (including new treatment centers), the company is strategically positioned to achieve market leadership and substantial revenue growth despite current operational unprofitability and execution challenges.
Is ABEO Stock Undervalued?
Unlock the full AI analysis for ABEO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ABEO Price Targets & Strategy
12-Month Target
$19.00
Bull Case
$25.00
Bear Case
$3.00
Valuation Basis
Based on average analyst target of $19, implying an estimated 19x future P/E applied to projected ~$1.00 FY2027 EPS.
Entry Strategy
Dollar-cost average between current levels and $4.00, identifying recent support zones. Consider buying dips towards the 50-day or 200-day SMA if they align with strong news flow.
Exit Strategy
Take 30-50% profit at the $18-$20 analyst targets. Consider a stop-loss order if the stock breaks below $3.50 (materially below book value and recent lows) indicating a failure in commercialization.
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ABEO Financially Healthy?
Valuation
P/E Ratio
1.01
Balance Sheet
Cash & Equivalents
$191.40M
Does ABEO Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
ZEVASKYN's FDA approval as a first-in-class gene therapy for an ultra-rare disease creates a significant and durable barrier to entry, supported by patent protection and regulatory exclusivity. The small patient population also disincentivizes multiple competitors.
Moat Erosion Risks
- •Development of a superior or more cost-effective alternative therapy (unlikely in short term)
- •Challenges in manufacturing scalability and cost efficiency
- •Reimbursement hurdles affecting patient access and commercial uptake
ABEO Competitive Moat Analysis
Sign up to see competitive advantages
ABEO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Limited specific data available but general interest in biotech breakthroughs.
Institutional Sentiment
Positive - HC Wainwright reiterated Buy, $20 target. Funicular Funds/Cable Car Capital/Jacob Ma-Weaver disclosed a 5.3% passive stake on March 27, 2026.
Insider Activity (Form 4)
Unnamed insider proposed sale of 29,985 restricted shares ($131,481 value) on March 31, 2026. A prior sale of 69,832 shares ($372,267) by an insider occurred on Jan 22, 2026. No CEO/CFO activity reported.
Options Flow
Normal options activity - No specific unusual options activity data provided.
Earnings Intelligence
Next Earnings
Estimated May 2026 (for Q1 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Q4 2025 revenue missed estimates, but EPS beat. Prior results show volatile net income due to one-off gains/losses. Stock reaction likely sensitive to ZEVASKYN commercialization metrics and forward guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No direct competitors for ZEVASKYN in RDEB gene therapy)
Market Share Trend
Gaining - ZEVASKYN is the first FDA-approved gene therapy for RDEB, positioning Abeona to capture the entire treatable market as commercialization scales.
Valuation vs Peers
Difficult to compare directly due to first-in-class product and unique market. Forward P/E of 19.08 is speculative given current losses; Price/Sales is extremely high (48x based on FY25 rev) reflecting high future growth expectations typical for early-stage biotechs.
Competitive Advantages
- •First-in-class FDA-approved gene therapy for RDEB
- •Regulatory exclusivity (Orphan Drug Designation, Breakthrough Therapy)
- •Strong intellectual property protection for ZEVASKYN
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ABEO Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated May 2026)
- •Activation of additional Qualified Treatment Centers for ZEVASKYN
- •Updates on ZEVASKYN patient enrollment and commercial ramp-up
Medium-Term (6-18 months)
- •Potential expansion of ZEVASKYN into new geographies or indications
- •Positive clinical data from pipeline candidates
- •Strategic partnerships to accelerate ZEVASKYN commercialization
Long-Term (18+ months)
- •ZEVASKYN becoming the standard of care for RDEB
- •Pipeline advancements yielding new gene therapy approvals
- •Establishing market leadership in rare genetic diseases
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABEO?
- ✓
Acceleration in quarterly ZEVASKYN product revenue and patient numbers.
- ✓
Improvement in operating margins and reduction in cash burn.
- ✓
Positive updates on pipeline development and new regulatory milestones.
Bull Case Analysis
See what could go right with Premium
Competing with ABEO
See how Abeona Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Abeona Therapeutics Inc ABEO | $292.1M | 7.9 | 1.0 | $5.8M | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Abeona Therapeutics Inc Makes Money
Abeona Therapeutics is a clinical-stage and commercial-stage biopharmaceutical company focused on developing and delivering gene and cell therapies for rare diseases. Its primary business currently revolves around the commercialization of ZEVASKYN, an FDA-approved gene therapy used to treat dystrophic epidermolysis bullosa (RDEB), an ultra-rare genetic skin disorder. The company generates revenue by selling this specialized therapy to patients who receive treatment at qualified medical centers, aiming to address critical unmet medical needs with innovative genetic solutions.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Abeona Therapeutics Inc (ABEO)?
As of April 12, 2026, Abeona Therapeutics Inc has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Abeona Therapeutics Inc?
Abeona Therapeutics Inc's market capitalization is approximately $292.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Abeona Therapeutics Inc use?
ABEO is the ticker symbol for Abeona Therapeutics Inc. The company trades on the NCM.
What is the risk level for ABEO stock?
Our analysis rates Abeona Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABEO?
Abeona Therapeutics Inc currently has a price-to-earnings (P/E) ratio of 1.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Abeona Therapeutics Inc's revenue growing?
Abeona Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ABEO stock profitable?
Abeona Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ABEO DVR analysis updated?
Our AI-powered analysis of Abeona Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABEO (Abeona Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.